BCL2 and acute myeloid leukemia: Early pre-clinical studies have shown that AML cells, especially leukemic stem cells, are dependent on BCL-2 for survival, and inhibition by venetoclax can lead to rapid apoptosis of AML cells and eradication of quiescent leukemic stem cells (26–29).